NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥8.8b

Last Updated

2021/04/17 09:18 UTC

Data Sources

Company Financials +

Executive Summary

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Getein Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 603387 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 603387's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-0.5%

603387

-0.2%

CN Biotechs

-0.8%

CN Market


1 Year Return

-5.1%

603387

33.0%

CN Biotechs

25.0%

CN Market

Return vs Industry: 603387 underperformed the CN Biotechs industry which returned 33% over the past year.

Return vs Market: 603387 underperformed the CN Market which returned 25% over the past year.


Shareholder returns

603387IndustryMarket
7 Day-0.5%-0.2%-0.8%
30 Day-0.03%9.5%-0.08%
90 Day4.1%2.9%-5.3%
1 Year-3.8%-5.1%33.4%33.0%27.0%25.0%
3 Year11.9%8.6%85.6%82.7%29.1%22.8%
5 Yearn/a74.7%71.4%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Getein Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Getein Biotech undervalued compared to its fair value and its price relative to the market?

28.34x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 603387 (CN¥34.01) is trading above our estimate of fair value (CN¥12.62)

Significantly Below Fair Value: 603387 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 603387 is good value based on its PE Ratio (28.3x) compared to the CN Biotechs industry average (55.1x).

PE vs Market: 603387 is good value based on its PE Ratio (28.3x) compared to the CN market (33.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 603387's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 603387 is good value based on its PB Ratio (5.1x) compared to the CN Biotechs industry average (6.3x).


Future Growth

How is Getein Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

21.8%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 603387's forecast earnings growth is above the savings rate (3.3%).

Earnings vs Market: Insufficient data to determine if 603387's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603387's revenue (21.8% per year) is forecast to grow faster than the CN market (17.7% per year).

High Growth Revenue: 603387's revenue (21.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 603387's Return on Equity is forecast to be low in 3 years time (19%).


Past Performance

How has Getein Biotech performed over the past 5 years?

19.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 603387 has high quality earnings.

Growing Profit Margin: 603387's current net profit margins (27.6%) are lower than last year (35.1%).


Past Earnings Growth Analysis

Earnings Trend: 603387's earnings have grown by 19.3% per year over the past 5 years.

Accelerating Growth: 603387's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603387 had negative earnings growth (-8.1%) over the past year, making it difficult to compare to the Biotechs industry average (17.7%).


Return on Equity

High ROE: 603387's Return on Equity (16.5%) is considered low.


Financial Health

How is Getein Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 603387's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥526.3M).

Long Term Liabilities: 603387's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥7.6M).


Debt to Equity History and Analysis

Debt Level: 603387's debt to equity ratio (15.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 603387's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 603387's debt is well covered by operating cash flow (85%).

Interest Coverage: 603387 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Getein Biotech current dividend yield, its reliability and sustainability?

1.18%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 603387's dividend (1.18%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).

High Dividend: 603387's dividend (1.18%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 603387 has been paying a dividend for less than 10 years.

Growing Dividend: 603387's dividend payments have increased, but the company has only paid a dividend for 3 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (33.3%), 603387's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 603387's dividends in 3 years are forecast to be well covered by earnings (27.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Getein Biotech has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Getein Biotech, Inc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Getein Biotech, Inc
  • Ticker: 603387
  • Exchange: SHSE
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥8.840b
  • Shares outstanding: 260.34m
  • Website: https://www.bio-gp.com.cn

Number of Employees


Location

  • Getein Biotech, Inc
  • No.9 Bofu Road
  • Luhe District
  • Nanjing
  • Jiangsu Province
  • 211505
  • China

Listings


Biography

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw mat...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:18
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.